Release Date: 26/04/22 08:20 Summary: Quarterly Activities/Appendix 5B Cash Flow Report Price Sensitive: Yes Download Document 2.4MB Download
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status